Davita Inc vs Financial Select Sector SPDR Fund — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Financial Select Sector SPDR Fund trades at $57.85. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | XLF | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | — |
52-Week High | $240.96 | $58.01 |
52-Week Low | $103.87 | $47.80 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
XLF trades at $57.60, down 0.35% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF recently touched an all-time high, supported by robust inflows into financial sector ETFs and strong Q2 earnings from major banks. A dividend of $0.19 is scheduled for June 2026, adding income appeal.
Outlook remains positive given sector strength and institutional interest, though overbought RSI levels suggest near-term consolidation risks. Key opportunities include diversification benefits and yield; risks involve interest rate sensitivity and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →